Efficacy and safety of bevacizumab-combined single-agent chemotherapy for platinum-resistant ovarian cancer that recurred during PARP inhibitor treatment

International Journal of Clinical Oncology 2026

View at publisher
Authors: Eriko Takatori, Tadahiro Shoji, Ami Jo, Miku Musashi, Shunsuke Tatsuki, Nanako Jonai, YOHEI CHIBA, Sho Sato, Yoshitaka Kaido, Takayuki Nagasawa, Masahiro Kagabu, Fumiaki Takahashi
+2 more Takeshi Aida, Tsukasa Baba
DOI: 10.1007/s10147-026-02959-7
Cited by: 1
References: 25

Fields of Study & Subjects

PARP inhibition in cancer therapy Ovarian cancer diagnosis and treatment Protein Degradation and Inhibitors

Publication details

Journal / source
International Journal of Clinical Oncology
Publisher
Springer Science and Business Media LLC
Volume
31
Issue
3
Pages
467–475
Publication date
17 January 2026
Language
EN